指南与共识消化与肝胆胰病理

胰腺胆道病理学会:新辅助治疗后胰腺切除标本病理检查建议

Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.
指南 / 共识 · Am J Surg Pathol · 2021-12-15

胰腺胆道病理学会新辅助治疗工作组于2018年成立,通过审查取材方案、文献和主要问题,制定了治疗后胰腺切除标本病理评估建议。建议包括系统标准化取材、连续 mapping 切片验证肿瘤大小、显微镜下测量肿瘤外限、采用 MD Anderson 分级系统、完整反应需提交全部胰腺及邻近组织、未来需研究淋巴结反应及分子标志物等。

要点

  • 采用系统标准化取材方案评估治疗后胰腺导管腺癌标本。
  • 沿肿瘤最大径连续 mapping 切片,显微镜下测量肿瘤外限大小。
  • MD Anderson 分级与预后相关性及观察者间一致性优于 CAP 系统。

核心结论

  • 系统标准化病理评估、准确测量肿瘤大小及可重复的治疗反应分级对新辅助治疗后胰腺导管腺癌患者最佳诊疗是必要的。

研究设计与样本

  • 胰腺胆道病理学会新辅助治疗工作组于2018年成立,审查取材方案、文献和主要问题并制定建议。

主要发现

  • 工作组就取材方案、肿瘤大小测量、肿瘤反应分级系统、完整反应判定标准及未来研究方向提出六条建议。
  • MD Anderson 肿瘤反应分级系统与预后相关性更好且病理医师间一致性优于 CAP 系统。

关键数值与推荐

  • 推荐沿肿瘤最大径连续 mapping 切片以组织学验证肿瘤大小,满足 CAP 癌症方案要求。
  • 治疗后 PDAC 肿瘤大小应显微镜下测量为有活肿瘤细胞(包括其间质)所限定的肿瘤外限最大径。
  • 仅当整个胰腺、胰周组织、壶腹部、胆总管及邻近十二指肠均提交镜检时,方可分类为完整反应。

临床怎么用

  • 病理科医师应采用标准化取材和 mapping 切片方案处理新辅助治疗后胰腺切除标本。
  • 肿瘤反应分级优先采用 MD Anderson 系统,完整反应判定需确保全部相关组织提交镜检。

局限性

  • 目前尚无国际公认的共识指南用于治疗后胰腺切除标本的病理评估。
  • 未来需研究淋巴结转移瘤反应、分子和/或免疫组化标志物及人工智能在分级中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, there are no internationally accepted consensus guidelines for pathologic evaluation of posttherapy pancreatectomy specimens. The Neoadjuvant Therapy Working Group of Pancreatobiliary Pathology Society was formed in 2018 to review grossing protocols, literature, and major issues and to develop recommendations for pathologic evaluation of posttherapy pancreatectomy specimens. The working group generated the following recommendations: (1) Systematic and standardized grossing and sampling protocols should be adopted for pancreatectomy specimens for treated pancreatic ductal adenocarcinoma (PDAC). (2) Consecutive mapping sections along the largest gross tumor dimension are recommended to validate tumor size by histology as required by the College of American Pathologists (CAP) cancer protocol. (3) Tumor size of treated PDACs should be measured microscopically as the largest dimension of tumor outer limits that is bound by viable tumor cells, including intervening stroma. (4) The MD Anderson grading system for tumor response has a better correlation with prognosis and better interobserver concordance among pathologists than does the CAP system. (5) A case should not be classified as a complete response unless the entire pancreas, peripancreatic tissues, ampulla of Vater, common bile duct, and duodenum adjacent to the pancreas are submitted for microscopic examination. (6) Future studies on tumor response of lymph node metastases, molecular and/or immunohistochemical markers, as well as application of artificial intelligence in grading tumor response of treated PDAC are needed. In summary, systematic, standardized pathologic evaluation, accurate tumor size measurement, and reproducible tumor response grading to neoadjuvant therapy are needed for optimal patient care. The criteria and discussions provided here may provide guidance towards these goals.

来源:Am J Surg Pathol,查看原文。版权归原作者所有。

引用

  1. Wang H, Chetty R, Hosseini M, et al. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society. Am J Surg Pathol. 2021. PMID: 34889852. doi:10.1097/PAS.0000000000001853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。